Faes Farma posted double-digit growth in sales, EBITDA, and net profit in H1 2024, driven by international expansion and strong pharma performance, while maintaining a robust balance sheet and increasing shareholder returns.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.